Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

135.58 -5.02 (-3.57%)

Streaming Delayed Price Updated: 1:38 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation ↗

May 03, 2024

Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.

Via Investor's Business Daily

Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review ↗

May 03, 2024

The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.

Via Investor's Business Daily

Topics Economy

Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. ↗

May 03, 2024

Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

NASDAQ:NBIX, a strong growth stock, setting up for a breakout. ↗

May 02, 2024

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences ↗

May 01, 2024

Via Benzinga

Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase. ↗

April 11, 2024

Via Chartmill

Where Neurocrine Biosciences Stands With Analysts ↗

April 10, 2024

Via Benzinga

Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗

May 02, 2024

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

Via Chartmill

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗

May 01, 2024

PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.

Via Investor's Business Daily

NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win ↗

May 01, 2024

The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia.

Via Investor's Business Daily

Sarepta Therapeutics Stock Shows Improved Technical Strength ↗

April 29, 2024

The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.

Via Investor's Business Daily

Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗

April 26, 2024

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

Via Investor's Business Daily

3 Red-Hot Biotech Rockets Blasting Off in 2024 ↗

April 24, 2024

The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.

Via InvestorPlace

Topics Economy

Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder ↗

April 23, 2024

Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in...

Via Benzinga

No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win ↗

April 23, 2024

The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.

Via Investor's Business Daily

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

April 16, 2024

From Sentia Medical Sciences, Inc.

Via GlobeNewswire

The 5 Stocks Most Sold By Insiders This Year

April 16, 2024

Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.

Via MarketBeat

NASDAQ:NBIX is not too expensive for the growth it is showing. ↗

March 20, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is showing decent growth, but is still valued reasonably.

Via Chartmill

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

March 20, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗

April 10, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

Via Chartmill

Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

April 05, 2024

In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind ↗

March 23, 2024

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

Via Investor's Business Daily

Topics Economy Stocks

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗

March 19, 2024

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...

Via Benzinga

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

March 18, 2024

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

Via Investor's Business Daily

Why Quality-Oriented Investors Should Consider NASDAQ:NBIX. ↗

March 15, 2024

Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

Decoding 8 Analyst Evaluations For Neurocrine Biosciences ↗

March 13, 2024

Via Benzinga

AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base ↗

March 16, 2024

Three of the featured stocks are closing in on record highs.

Via Investor's Business Daily

Topics Artificial Intelligence

NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying. ↗

March 14, 2024

When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences ↗

March 13, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.